GSK plc (GLAXF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Brentford, United Kingdom. Der aktuelle CEO ist Luke Victor Miels.
GLAXF hat IPO-Datum 2010-01-05, 68,629 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $116.84B.
GSK plc is a global pharmaceutical and healthcare company headquartered in the United Kingdom, engaged in the discovery, development, and commercialization of prescription medicines, vaccines, and consumer health products across multiple therapeutic areas and markets worldwide. The company operates four primary business segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare, offering treatments in respiratory, HIV, oncology, immunology, cardiovascular, and other disease categories, alongside consumer wellness and oral health products. GSK maintains an extensive portfolio of consumer healthcare offerings including nasal sprays, tablets, lozenges, toothpastes, and topical formulations across multiple dosage forms. The company strengthens its innovation pipeline through strategic collaborations with leading biotechnology firms including Novartis, Sanofi, and Vir Biotechnology, positioning itself as a diversified player in both prescription pharmaceuticals and consumer health markets. Founded in 1715 and rebranded as GSK plc in 2022, the company maintains significant operations across the United Kingdom, United States, and international markets.
